A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do not have cancer in situ (CIS) but do have high grade papillary urothelial cancer. Eligible patients will be enrolled to receive up to 13 cycles of monthly combination of monalizumab and durvalumab. Both monalizumab and durvalumab will be administered intravenously (IV) every 28 days.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Chęć i możliwość udziału w badaniu przez cały jego czas, w tym leczenie i wizyty kontrolne
- •Dobry ogólny stan zdrowia (ocena ECOG do 1 punktu)
- •Rak pęcherza niewylegający poza mięśnie (Grupa A: rak zaawansowany bez przebicia mięśni, z guzkoflatością lub bez, Grupa B: tylko guzkoflatość bez zaawansowanego raka)
- •Ukończone co najmniej 5 dawek wstępnego leczenia BCG i następna faza leczenia
- •Rak nie poddał się leczeniu BCG lub powrócił mimo leczenia BCG
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
University of California San Francisco
San Francisco, United States
Moffitt Cancer Center
Tampa, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Weill Cornell Medical Center
New York, United States
Trial contact
John Sfakianos, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.